Hybrid Ganciclovir/Valacyclovir Prophylaxis Reduces CMV Reactivation in High-Risk Allogeneic Stem Cell Transplant Recipients. (PubMed, Int J Hematol Oncol Stem Cell Res) - May 5, 2026 - "Background: Cytomegalovirus (CMV) reactivation remains a critical concern following allogeneic hematopoietic stem cell transplantation (allo-HSCT), particularly in CMV-seropositive patients undergoing allo-HSCT from alternative donors. However, no statistically significant differences were observed in the overall survival, disease-free survival, or non-relapse mortality. The hybrid regimen reduced CMV reactivation in high-risk HSCT recipients but did not improve survival outcomes, offering a practical alternative in settings with limited access to Letermovir."
Journal • Bone Marrow Transplantation • Cytomegalovirus Infection • Graft versus Host Disease • Hematological Malignancies • Immunology • Leukemia • Oncology • Transplantation
|
|
Amirabbas Rashidi; Hosein Kamranzadeh Fumani; Maryam Barkhordar; Mehrdad Abbaszadeh; Mohammad Vaezi; Neda Alijani; Sahar Tavakoli Shiraji; Seied Asadollah Mousavi; Tanaz Bahri
|